Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02670941 · ClinicalTrials.gov registry record · Early Phase 1
Aromatherapy for Chemotherapy-induced Symptoms
A Early Phase 1 study, sponsored by University of Rochester.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 31
- Enrollment target
NCT02670941: Clinical Trial Early Phase 1 study, sponsored by University of Rochester.
NCT02670941 is a Early Phase 1 study that was terminated before completion, run by University of Rochester. The registered enrollment target is 31 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02670941, a Early Phase 1 study, was terminated before completion, sponsored by University of Rochester.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The rationale behind the proposed study is to determine the initial effectiveness of aromatherapy in relief of commonly reported symptoms in cancer patients undergoing chemotherapy.
Primary Outcome
Subjects will complete a self-report Symptom Inventory Diary during each Study Cycle starting at Day 0 and continuing to Day 6. Subjects will rate the severity of seven symptoms (nausea, vomiting, pain, anxiety/distress, sleep difficulties, fatigue, and lack of appetite) using a 0-10 numeric rating scale, with 10 indicating a higher severity, in daily diary format.
Interventions
- DRUG Ginger
- DRUG Lavender
- DRUG Orange
- DRUG Jojoba
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2016-01 |
| Est. Completion | 2018-09-12 |
| Phase | Early Phase 1 |
Why NCT02670941 stopped before completion
NCT02670941 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (42% lower).
The record links to 0 conditions, and to 4 interventions - of which Ginger is the first listed.
NCT02670941 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02670941 about?
NCT02670941 is a clinical study titled "Aromatherapy for Chemotherapy-induced Symptoms". The rationale behind the proposed study is to determine the initial effectiveness of aromatherapy in relief of commonly reported symptoms in cancer patients undergoing chemotherapy.
What is the current status of trial NCT02670941?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 31 participants. The study started on 2016-01. Estimated completion is 2018-09-12.
What interventions are being tested in trial NCT02670941?
The interventions under investigation include: Ginger (DRUG), Lavender (DRUG), Orange (DRUG), Jojoba (DRUG).
Who is sponsoring clinical trial NCT02670941?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02670941's enrollment target sits among peer trials
31 794th of 2000 higher than 1,194 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia